ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04539-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Amanda B Kagan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Clinical Pharmacology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antimalarials, Artemisinins, Leukemia, Myeloid, Acute. Die Arbeit nennt 36 Literaturangaben. Gefördert von: NCRR NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE: It has become increasingly clear that new multiagent combination regimens are required to improve survival rates in acute myeloid leukemia (AML). We recently reported that ART631, a first-in-class 2-carbon-linked artemisinin-derived dimer (2C-ART), was not only efficacious as a component of a novel three-drug combination regimen to treat AML, but, like other synthetic artemisinin derivatives, demonstrated low clinical toxicity. However, we ultimately found ART631 to have suboptimal solubility and stability properties, thus limiting its potential for clinical development. METHODS: We assessed 22 additional 2C-ARTs with documented in vivo antimalarial activity for antileukemic efficacy and physicochemical properties. Our strategy involved culling out 2C-ARTs inferior to ART631 with respect to potency, stability, and solubility in vitro, and then validating in vivo pharmacokinetics, pharmacodynamics, and efficacy of one 2C-ART lead compound. RESULTS: Of the 22 2C-ARTs, ART714 was found to have the most optimal in vitro solubility, stability, and antileukemic efficacy, both alone and in combination with the BCL2 inhibitor venetoclax (VEN) and the kinase inhibitor sorafenib (SOR). ART714 was also highly effective in combination with VEN and the FMS-like tyrosine kinase 3 inhibitor gilteritinib (GILT) against MOLM14 AML xenografts. CONCLUSION: We identified ART714 as our best-in-class antileukemic 2C-ART, based on in vitro potency and pharmacologic properties. We established its in vivo pharmacokinetics and demonstrated its in vitro cooperativity with VEN and SOR and in vivo activities of combinations of ART714, VEN, and GILT. Additional research is indicated to define the optimal niche for the use of ART714 in treatment of AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Clinical Pharmacology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
- Department of Oncology, School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231-1000, USA.
- Departments of Pediatrics and Physiology, School of Medicine, Center for Stem Cell Biology and Regenerative Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, BRB14-021, 655 W…
- Keros Therapeutics, Inc., Lexington, MA, USA.
- Department of Medicine, School of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
- Department of Neurosurgery, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Förderung
- NCRR NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- NIH HHS
- Emmert Hobbs Foundation Endowment
- Maryland Technology Development Corporation
- Maryland Industrial Partnerships
Zitieren
APA
Kagan, A. B., Moses, B. S., Lapidus, R., Mott, B. T., Rai, G., Anders, N. M., Hoag, S. W., Rudek, M. A., & Civin, C. I. (2023). ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04539-2
Vancouver
Kagan AB, Moses BS, Lapidus R, Mott BT, Rai G, Anders NM, et al. ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04539-2
BibTeX
@article{Kagan2023,
author = {Kagan, Amanda B and Moses, Blake S and Lapidus, Rena and Mott, Bryan T and Rai, Ganesha and Anders, Nicole M and Hoag, Stephen W and Rudek, Michelle A and Civin, Curt I},
title = {ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04539-2}
}
EUVIMED